Solidpharma

Solidpharma has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €733,170 and a net result of €163,718. Equity is shrinking by ~3.7% per year across the filed fiscal years. Its solvency ranks better than 45% of 12396 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).